The concept of "normalization" of tumor vasculature induced by bevacizumab, developed by Jain [28] who demonstrated with some colleagues this effect of VEGF blockade in rectal carcinoma [29], may therefore explain the circumvention of resistance to conventional therapies observed in our study. The gene discussed is VEGFA; the disease is rectal carcinoma.